Increasing plasma adiponectin level or increasing adiponectin sensitivity with the aid of PPARγ agonists has been proposed as a promising therapeutic strategy for patients with metabolic and/or cardiovascular disease [27]. This evidence concerns the gene ADIPOQ and cardiovascular disorder.